Antikoagulační terapie dabigatranem vs rivaroxabanem u seniorů ve věku nad 65 let: porovnání dat „head to head“

1. Čihák R, Haman L, Táborský M et al. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Cor et vasa 2016; 58(6): 728–771.

2. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation dveloped in Collaboration with EACTS. Europace 2016; 18(11): 1609–1678.

3. Graham DJ, Reichman ME, Wernecke M et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176(11): 1662–1671.

4. Schaefer JK, McBane RD, Wysokinski WE. How to Choose Appropriate Direct Oral Anticoagulant for Patient with Nonvalvular Atrial Fibrillation. Ann Hematom 2016; 95(3): 437–449.

5. Shenasa M, Camm JA. Management of Atrial Fibrillation. Oxford University Press: Oxford 2015. ISBN 978–0-19–968631–5.